

## **INFORMATIONAL LETTER NO. 2528-MC-FFS-D**

**DATE:** December 1, 2023

TO: Iowa Medicaid Physicians, Dentists, Advanced Registered Nurse

Practitioners, Therapeutically Certified Optometrists, Podiatrists,

Pharmacies, Home Health Agencies, Rural Health Clinics, Clinics, Skilled Nursing Facilities, Intermediate Care Facilities, Nursing Facilities – Mental ILL, Federally Qualified Health Centers, Indian Health Service, Maternal Health Centers, Certified Nurse Midwife, Community Mental Health, Family Planning, Residential Care Facilities, ICF/ID State and Community-

Based ICF/ID Providers, Physician Assistants

**APPLIES TO:** Managed Care (MC), Fee-for-Service (FFS), Dental (D)

FROM: Iowa Department of Health and Human Services (HHS), Iowa Medicaid

**RE:** SUPPORT Act Section 5042(e)(1)(A) Reporting Requirements Survey for

Federal Fiscal Year (FFY) 2023

**EFFECTIVE:** Immediately

Section 5042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, codified in 42 U.S.C. 1396w-3a<sup>1</sup>, requires covered providers who are permitted to prescribe controlled substances and who participate in Medicaid to query qualified prescription drug monitoring programs (PDMPs) before prescribing controlled substances to most Medicaid beneficiaries. In Iowa, the PDMP is known as the Prescription Monitoring Program (PMP) or Iowa PMP AWARxE<sup>2</sup>.

Documentation of the query of the database within the PMP must be made in the member's file by the prescribing provider. Subject to the requirements under <u>lowa Code chapter 124</u><sup>3</sup>, subchapter VI, if the provider is not able to conduct a review of the PMP, the member's file should include the reasons the provider was not able to complete the review. Upon request of the lowa Medicaid program, the prescribing provider shall submit the documentation.

<sup>1</sup> https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1396w-3a&num=0&edition=prelim

<sup>&</sup>lt;sup>2</sup> <u>https://iowa.pmpaware.net/login</u>

<sup>&</sup>lt;sup>3</sup> https://www.legis.iowa.gov/docs/ico/chapter/124.pdf

This does not apply to Medicaid members who are receiving inpatient hospice care or long-term residential facility care. Notification of provider requirements for prescribing controlled substances was provided in <u>Informational Letter (IL) NO. 2280-MC-FFS-D</u><sup>4</sup>.

Section 1927(g)(3)(D) of the Social Security Act (the Act) requires each state to submit an annual report on the operation of its Medicaid Drug Utilization Review (DUR) program. Centers for Medicare & Medicaid (CMS) has included questions to reference metrics for compliance with provisions outlined in Section 5042 of the SUPPORT Act. Mandatory State reporting to CMS begins with the FFY 2023 DUR survey and will continue annually.

Please complete the <u>survey</u><sup>5</sup> regarding your prescribing practices for FFY 2023, from October 2022 through September 2023. The survey is open effective immediately and will close on February 16<sup>th</sup>, 2024 at 11:59 pm CST.

If you have questions, please contact Iowa Medicaid Provider Services:

## **Iowa Medicaid Provider Services:**

• Phone: I-800-338-7909

• Email: <u>imeproviderservices@dhs.state.ia.us</u>

2

<sup>&</sup>lt;sup>4</sup> https://secureapp.dhs.state.ia.us/IMPA/Information/Bulletins.aspx

<sup>&</sup>lt;sup>5</sup> https://forms.office.com/g/65uVRTZmh5